Freestone Grove Partners’s AbbVie ABBV Stock Holding History

Freestone Grove Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$435	–	992
2026 Q1	$435	Buy	+2	New	+$444	﹤0.01%	888
2025 Q4	–	Sell	-294,201	Closed	-$68.1M	–	716
2025 Q3	$68.1M	Buy	294,201 +12,893	+5%	+$2.63M	0.51%	47
2025 Q2	$52.2M	Buy	+281,308	New	+$52.3M	0.39%	88
2025 Q1	–	Sell	-7,601	Closed	-$1.35M	–	571
2024 Q4	$1.35M	Buy	+7,601	New	+$1.4M	0.02%	282

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Freestone Grove Partners's ABBV Position: Q2 2026 in Review

Freestone Grove Partners sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 2 shares — an estimated $435 sold.

Freestone Grove Partners first reported a position in ABBV in Q4 2024 and held it in 4 quarters. The position peaked at $68.1M in Q3 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Freestone Grove Partners reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Freestone Grove Partners sold 2 AbbVie shares in Q2 2026, an estimated $435.
Freestone Grove Partners first reported a position in AbbVie in Q4 2024 and held it in 4 quarters.
Freestone Grove Partners's AbbVie position peaked at $68.1M in Q3 2025.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.